FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer

Key Takeaways FDA accepted Corcept's NDA for relacorilant in platinum-resistant ovarian cancer.NDA backed by positive phase III ROSELLA and phase II study data with relacorilant nab-paclitaxel.Decision on CORT's NDA for relacorilant in ovarian cancer is expected from the FDA by July 11, 2026.Corcept Therapeutics (CORT) announced that the FDA has accepted the new drug application (NDA) seeking approval for its lead pipeline candidate, relacorilant, for treating patients with platinum-resistant ovarian cancer ...